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AbstrACt
Introduction Patients with paediatric- onset inflammatory 
bowel disease (PIBD) may develop a complicated disease 
course, including growth failure, bowel resection at young 
age and treatment- related adverse events, all of which 
can have significant and lasting effects on the patient’s 
development and quality of life. Unfortunately, we are 
still not able to fully explain the heterogeneity between 
patients and their disease course and predict which 
patients will respond to certain therapies or are most at 
risk of developing a more complicated disease course. 
To investigate this, large prospective studies with long- 
term follow- up are needed. Currently, no such European 
or Asian international cohorts exist. In this international 
cohort, we aim to evaluate disease course and which 
patients are most at risk of therapy non- response or 
development of complicated disease based on patient 
and disease characteristics, immune pathology and 
environmental and socioeconomic factors.
Methods and analysis In this international prospective 
observational study, which is part of the PIBD Network 
for Safety, Efficacy, Treatment and Quality improvement 
of care (PIBD- SETQuality), children diagnosed with 
inflammatory bowel disease <18 years are included at 
diagnosis. The follow- up schedule is in line with standard 
PIBD care and is intended to continue up to 20 years. 
Patient and disease characteristics, as well as results 
of investigations, are collected at baseline and during 
follow- up. In addition, environmental factors are being 
assessed (eg, parent’s smoking behaviour, dietary factors 
and antibiotic use). In specific centres with the ability to 
perform extensive immunological analyses, blood samples 
and intestinal biopsies are being collected and analysed 
(flow cytometry, plasma proteomics, mRNA expression 
and immunohistochemistry) in therapy- naïve patients and 
during follow- up.
Ethics and dissemination Medical ethical approval has 
been obtained prior to patient recruitment for all sites. 
The results will be disseminated through peer- reviewed 
scientific publications.
trial registration number NCT03571373.
IntroduCtIon
background
Paediatric- onset inflammatory bowel disease 
(PIBD) is a chronic disease that often leads 
strengths and limitations of this study
 ► International prospective observational study with 
long- term follow- up examining clinical phenotype 
and biomarkers that may be predictive for compli-
cated disease course, serious adverse events and 
response (or not) to therapy.
 ► The ability to perform extensive immunological 
analysis (eg, flow cytometry, plasma proteomics, 
messenger RNA expression and immunohistochem-
istry) of peripheral blood leucocytes and biopsies 
in therapy- naïve patients to evaluate heterogeneity 
at diagnosis and to follow- up these immunological 
parameters during disease course and therapy use.
 ► The first prospective PIBD cohort that includes 
patients from several European and some Asian 
countries, which enables comparison of therapeutic 
strategies between countries and continents, and 
outcomes of these strategies.
 ► Large scale collection of quality of life measures (eg, 
IMPACT III and EQ- 5D questionnaires) to correlate to 
clinical findings and compare this across countries 
and ethnicities.
 ► Different methods between centres for measure-
ment of laboratory parameters that are part of stan-
dard clinical care serve as a limitation to this study.
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to disabling symptoms such as abdominal pain, diarrhoea 
and rectal bleeding. Inflammatory bowel disease (IBD) 
comprises Crohn’s disease (CD), ulcerative colitis (UC) 
and IBD unclassified (IBD- U). Although IBD is most 
frequently known as an adult disease, in 5%–25% of cases, 
it is diagnosed during childhood or adolescence.1–3 The 
incidence of IBD in Western Europe and North America 
ranges from 1.85 to 23.82 per 100 000 for CD and 1.9 to 
23.14 per 100 000 for UC.4 Despite the fact that the inci-
dence of IBD varies among different countries, a current 
concern is that the general trend shows increasing inci-
dence rates over recent decades, especially among the 
patients <10 years of age.1 3 5–7 Compared with adult- onset 
IBD, PIBD reflects a more severe disease.8–10 Conse-
quences of the disease, such as growth failure and bowel 
resection at a young age, may have a large impact on the 
patient’s further development and quality of life (QoL). 
In addition, the early onset of this disease regularly leads 
to an early use of intensive therapies with a life- long risk 
of treatment- related adverse events.8 11–13
The pathogenesis of PIBD is currently partly explained 
by a combination of a genetic predisposition, microbial 
factors and susceptibility of the immune system leading 
to an aberrant inflammatory immune response.14–16 
Treatment strategies therefore focus on modulating or 
suppressing the immune response using immunosup-
pressive drugs or biologicals. Despite the known hetero-
geneity within paediatric patients with CD and UC at 
both disease diagnosis and during follow- up, we are still 
not able to predict which patients are at risk of devel-
oping a complicated disease course and which patients 
will respond to therapy.17 18 Therefore, the majority of 
patients with PIBD have been treated following a step- up 
approach, a strategy in which patients start with a simpler, 
easily available therapy at the bottom of the therapeutic 
pyramid and medications at the top are often consid-
ered more efficacious but may present greater risk to the 
patient. This approach may lead to a delay in treatment 
response and increases the risk of ongoing inflammation 
risking penetrating and stricturing complications. The 
ability to predict complicated disease course and response 
or non- response to therapy would be of immense value. 
This is essential to develop strategies that balance, on an 
individual basis, therapeutic effectiveness with risks of 
treatment.
In studies including adult patients with IBD, several clin-
ical risk factors have been identified for the development 
of a complicated disease course in CD and the need for 
colectomy in patients with UC.19 20 Given the differences 
in disease phenotype, course of disease and benefits and 
risks of treatment between children and adults, findings 
from studies in adult patients with IBD do not directly 
apply to PIBD. Few studies have assessed risk factors in 
patients with paediatric- onset CD and found that both 
stricturing disease behaviour17 21 22 and older age at diag-
nosis23–25 are associated with an increased risk for the 
need for surgery. In patients with paediatric- onset UC, 
the Paediatric Ulcerative Colitis Activity Index (PUCAI) 
at diagnosis and 3 months after diagnosis is found to be 
an essential predictor of colectomy.26 27 Kugathasan et 
al demonstrated that early anti- tumour necrosis factor 
(TNF) therapy in CD was associated with a decreased risk 
of penetrating but not stricturing complications.28
Due to the small number of available studies comprising 
a large variety of data on several different outcomes and 
predictors combined with a mainly retrospective set- up, to 
date, most findings regarding predictors of disease course 
in PIBD are inconclusive. The majority of the identified 
predictors are demographic or associated with the disease 
phenotype, and studies lack findings on the predic-
tive value of biomarkers. Despite the known role of the 
immune system in PIBD, no immunological biomarkers 
have been identified to correlate with the disease pheno-
type or disease course. Therefore, there is an urgent need 
to generate a prospective long- term real- world cohort 
designed to analyse effectiveness and safety signals with 
the ability to correlate them to individual risk factors in 
well- phenotyped patients. To address this issue, the Paedi-
atric Inflammatory Bowel Diseases Network for Safety, 
Efficacy, Treatment and Quality (PIBD- SETQuality) 
inception cohort was designed. Besides a few prospective 
PIBD cohorts, established in the USA and Canada, no 
international European cohorts currently exist to assess 
this.28 Due to possible differences in genotype, environ-
mental influences and treatment algorithms, European 
data are required. With this paper, we aim to inform the 
IBD research community about the existence of the PIBD- 
SETQuality inception cohort and provide insight into the 
establishment of this cohort.
objectives
PIBD- SETQuality is an international project with the 
overall goal to develop and validate a treatment algo-
rithm for PIBD based on high- risk or low- risk predictors 
for early complicated or relapsing disease. In this incep-
tion cohort, predictors of disease course are identified 
through prospective collection of longitudinal PIBD data 
in the first cohort that includes patients from several Euro-
pean and some Asian centres. Table 1 depicts the poten-
tially relevant prognostic factors listed by the consortium, 
which formed the basis of parameters to investigate in 
this study.
The main objective of this study is to facilitate the 
discovery of predictors of disease course, treatment 
response or non- response and severe adverse events in 
patients with PIBD by:
1. Collecting real- world longitudinal data with preferably 
a 20- year follow- up period.
2. Collecting biomaterials and linking this to the detailed 
clinical data.
3. Using standardised questionnaires to assess QoL.
In addition, this cohort enables investigation of PIBD 
heterogeneity based on immunological biomarkers and 
racial or environmental factors. Patients of differing 
ethnicities in the European countries will be included 
along with patients from some non- European countries, 
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Table 1 Potentially relevant prognostic factors in prediction 
of disease course and therapy responsiveness in PIBD




4 Severity of disease at diagnosis
5 Disease localisation
6 Course of disease
7 Level of inflammatory markers






14 Health economic status
15 Psychosocial status
Table 2 Visit schedule and included activities for PIBD- SETQuality inception cohort

















after start of 
therapy
18 months 
after start of 
therapy
24, 36 months 
and so on
Activity
Study explained, informed 
consent
X
Collection of routine clinical and 
laboratory data, including faecal 
calprotectin
X X X X X X X X
Extra blood sample taken at time 
of routine blood draw (maximum 
of 20 mL)*
O O O O O O O O
Extra biopsies taken at time of 
clinically required colonoscopy 
(maximum of 8)*
O O
Tissue sample in case of 
indication for surgical resection*
O O O O O O O
Environmental questionnaire X
IMPACT III and EQ- 5D 
questionnaires
X (both) X (EQ- 5D) X (EQ- 5D) X (both) X (EQ- 5D) X (both)
School attendance and WPAI 
questionnaires
X (both) X (both) X (both) X (both)
*This activity will only be performed in patients included in the subcohort. ‘X’ is performed in all patients, ‘O’ is only performed in patients included in the subcohort.
WPAI, Work Productivity and Activity Impairment.
which can allow comparison of different races in immi-
grant and non- immigrant subgroups.
MEthods And AnAlysIs
study design
The PIBD- SETQuality inception cohort is a multicentre 
prospective observational study in patients with PIBD. 
Participants are followed from the moment of diagnosis 
up to 20 years thereafter. During the first year after diag-
nosis, data collection is performed more frequently and 
reduced to annual visits after the second year of follow- up 
(table 2).
At least 535 patients with PIBD need to be included in 
the inception cohort. However, since this is an observa-
tional study, depending on the feasibility, the study will 
aim to recruit 1000 patients. In specific centres with the 
capacity to perform immunological analyses, participants 
are included in a subcohort for additional collection of 
biological specimens. This allows in- depth characterisa-
tion of immunological pathways in 100 patients with CD 
and 50 patients with UC and provides the opportunity to 
relate predictive factors to underlying immune dysfunc-
tion during follow- up. The inception cohort is part of the 
PIBD- SETQuality project, which is funded by Horizon 
2020.
Eligibility criteria
Children and adolescents <18 years with a likely or 
confirmed diagnosis of IBD are eligible. Diagnosis has 
to be made or confirmed within the first 2 months after 
inclusion. Diagnosis must be based on history, phys-
ical examination, laboratory, endoscopic, radiological 
and histological features according to the revised Porto 
criteria.29 If a diagnosis of IBD is not confirmed after the 
investigations are complete, the patient will be excluded 
from follow- up. Other inclusion criteria comprise avail-
able data on all diagnostic procedures for inclusion in 
the database, informed consent of patient and parents 
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Figure 1 Different immunological analyses that will be 
performed. Data will be correlated to the clinical data. IHC, 
immunohistochemistry; ISH, in situ hybridisation.
according to the national guidelines, and in case of inclu-
sion in the subcohort for collection of biomaterial, the 
patient has not started therapy yet at the moment of diag-
nostic endoscopy. Patients are excluded from this study: 
(1) when they are on similar treatments as for IBD but 
for other conditions, defined as the use of any biological, 
immunosuppressant or systemic corticosteroid; (2) when 
they are known to have conditions directly affecting IBD 
(eg, immunodeficiency or major gastrointestinal resec-
tions); and (3) in case of inability to read or understand 
the patient and family information sheets.
recruitment and data collection
All eligible patients are asked for informed consent to 
participate in the inception cohort. Within this study, clin-
ical data and results of questionnaires will be collected in 
all patients. Biomaterial is collected as part of the subco-
hort in specific centres with the ability to perform immu-
nological analyses.
Clinical data
At baseline, data on demographics, family history, diag-
nosis, disease activity, disease localisation and results of 
physical examination, endoscopy, radiographic imaging 
and laboratory results, including faecal calprotectin 
levels, are collected. Validated scores and classifications 
such as the weighted Paediatric Crohn’s Disease Activity 
Index (wPCDAI), PUCAI, Simple Endoscopic Score for 
Crohn’s Disease and Ulcerative Colitis Endoscopic Index 
of Severity are used.30–33 During follow- up, the clinical 
disease activity scores, results of additional investigations 
and detailed treatment information are collected at fixed 
time points and during hospitalisations.
Questionnaires
To assess the QoL, the validated IMPACT III question-
naire is being used. This questionnaire is a disease- specific 
health- related assessment of QoL, divided in the domains 
emotional functioning, social functioning, body image 
and well- being.34 35 Validated EQ- 5D questionnaires are 
being used to assess the health status of the patient (EQ- 
5D- Y and EQ- 5D- Y proxy) and the parents (EQ- 5D- 5L). 
The EQ- 5D questionnaire consists of five dimensions: 
mobility, self- care, usual activities, pain/discomfort 
and anxiety/depression.36 Parent’s work productivity is 
assessed by the Work Productivity and Activity Impairment 
questionnaire (WPAI) for caregivers. All validated ques-
tionnaires are used in accordance with their respective 
instructions regarding age limits. If validated translations 
of the IMPACT III, EQ- 5D and WPAI are not available in 
a certain language, patients in the respective country will 
not complete these questionnaires. Due to the lack of vali-
dated questionnaires assessing the child’s school atten-
dance, a non- validated questionnaire is being used to 
address this subject. The frequency of the assessment of 
these questionnaires is shown in table 2. At baseline, many 
environmental factors are being assessed comprising, for 
example, parent’s smoking behaviour, antibiotic use, sun 
exposure, previous enteritis and appendectomy. Assess-
ment of dietary factors is limited to assessing: (1) whether 
children are following a vegetarian or vegan diet and (2) 
if they are excluding specific items from their diet.
Biomaterial
In several centres, biological specimens are collected in 
addition to the clinical data. When informed consent for 
the collection of biomaterial is obtained, blood samples 
and intestinal biopsies are collected prior to treatment 
initiation and during follow- up visits in concurrence with 
routine clinical diagnostics. At diagnosis, in all patients, 
biopsies are collected from affected and non- affected 
tissue in both ileum and colon according to the stan-
dard operating procedure written for this study (online 
supplementary figure 1). During follow- up endoscopies, 
collection of ileum biopsies is optional and based on 
the clinician’s decision in patients with UC. Analyses of 
biopsies include immunohistochemistry, targeted quan-
titative messenger RNA (mRNA) analyses and unbiased 
mRNA sequencing analyses. Peripheral blood samples 
are collected for plasma proteomics analyses, plasma anti-
microbial reactivity, in- depth phenotypic and functional 
leucocyte analyses and screening for genetic polymor-
phisms (figure 1). Immunological analyses will be related 
to the previously described clinical data that is being 
collected. Patients enrolled in the subcohort in whom the 
diagnosis of IBD is not confirmed after additional investi-
gations will be analysed as non- IBD controls.
outcome measures
This study design and statistical analysis plan are based 
on one primary and several secondary and exploratory 
outcomes. At baseline, prior to the start of therapy, 
the clinical characteristics of patients with PIBD will 
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be reviewed and compared by country, as well as racial 
background. In patients participating in the subcohort, 
immunological biomarkers are reviewed in order to clas-
sify disease heterogeneity based on underlying immune 
pathology. Thereto, immunological parameters will be 
related to clinical and morphological disease features at 
this time point.
The primary outcome is clinical remission at 1 year, 
which reflects our aim to study therapy response and non- 
response. Clinical remission is defined as a wPCDAI <12.5 
in patients with CD and a PUCAI <10 in patients with UC 
or IBD- U. According to the set hypothesis, the disease 
localisation, extension, behaviour and type of induction 
therapy are important factors that influence the primary 
outcome, while age at diagnosis and the initial disease 
activity score are expected to be important covariates. In 
addition, biochemical and immunological parameters at 
baseline will be evaluated to predict clinical remission. In 
a subanalysis, the effect of early use of immunomodula-
tors and biologicals (less than 3 months from diagnosis) 
on remission rates will be investigated by comparing 
groups with early and later use.
One of the secondary outcomes of this study is to assess 
clinical remission over a period of 3 and 6 months since 
the start of treatment to evaluate short- term response. In 
addition, the need for treatment intensification within 
1 year will be assessed. The longitudinal follow- up analyses 
of individual immunological biomarkers will reveal which 
immune parameters change when patients are in clin-
ical remission. Clinical, biochemical and immunological 
findings at baseline and 12 weeks after the start of therapy 
will be assessed for their predictive value on the disease 
course after 1, 3, 5, 10, 15 and 20 years of follow- up. Lastly, 
as a longer term secondary outcome, we will assess: (1) 
moderate or severe disease over the last 6–12 months, (2) 
the development of complications such as fibrostricturing 
disease, penetrating disease, active perianal fistula or an 
abscess, (3) the need for IBD- related luminal surgery and 
(4) the need for biological use or need for treatment 
intensification, after 1, 3, 5, 10, 15 and 20 years.
As an exploratory outcome, the initial management 
of newly diagnosed patients with PIBD will be evaluated. 
The type of induction therapy and proportion of patients 
started on early immunomodulators or anti- TNF agents 
will be assessed and compared by country or region. 
Several environmental factors will be evaluated to assess 
their possible role in the heterogeneity of the presenting 
phenotype as well as disease course. Lastly, longitudinal 
findings on QoL, health status, parents’ work produc-
tivity and child’s school attendance will be evaluated, 
compared by country or region and correlated to disease 
activity and disease course.
sample size calculation
To ensure that the study is adequately powered for the 
primary outcome, we have calculated the minimum 
required sample size, which we have also adjusted for a 
10% expected information loss and multiple comparisons. 
To maintain the global significance level alpha at 0.05, for 
the sample size calculations, we decreased the significance 
level for the univariate analyses to 0.01 per Bonferroni 
correction. As we aim to capture predictors with signifi-
cant influence on clinical remission, we set the effect size 
of the primary outcome at 25%. In order to detect a 25% 
or higher difference between the compared groups, as 
defined by disease characteristics and therapy induction 
types and considering the variable sampling ratio (2:1 to 
1:2 depending on the factor), we will need 203 patients 
with CD and 214 patients with UC/IBD- U. Considering 
approximately 40% of PIBD diagnoses comprises UC/
IBD- U, we will need 535 patients with PIBD. Subsequently, 
the CD group will have slightly increased power than the 
originally planned 80%.
data collection and management
Data are collected in REDCap, a secured database, by 
using online case report forms (CRFs). CRFs are based 
on the dataset of the Canadian inception cohort by the 
Canadian Children Inflammatory Bowel Disease Network 
(CIDsCaNN) and adjusted to the needs of this study. A 
monitor performs remote (digital) monitoring for each 
participating centre yearly after inclusion. The coordi-
nating investigator runs consistency checks on a monthly 
basis and produces queries to be resolved by the local inves-
tigators. To secure accurate comparison of biomarkers in 
tissue specimens obtained from different centres, highly 
reproducible sample preparation is required across all 
centres participating in this study. Therefore, all aspects 
of sample acquisition and all reagents will be strictly regu-
lated, and sample quality will be tightly monitored.
Analysis and statistical methods
Data analysis will be performed with SPSS V.26 or higher 
for Windows and R version 3.6 or higher (R Foundation 
for Statistical Computing, Vienna, Austria). Descriptive 
statistics will be computed overall and per disease (CD and 
UC). Phenotypic grouping will be performed according 
to specific disease characteristics (eg, age of onset, disease 
localisation and disease behaviour). Next to this, patients 
will be categorised according to treatment categories. 
The appropriate descriptive statistics will be used to 
summarise the demographic characteristics. The primary 
outcome will be analysed using a 2- proportion Z test for 
the comparison of the different groups in our sample, 
using a stricter confidence level of 0.01 per Bonferroni 
correction. All proportions will be summarised per group, 
and 95% CIs will be provided. The important factors from 
the univariate analysis will be used to build a generalised 
linear model with a logit link function. This will be a 
multiple analysis of the effects that the selected factors 
and covariates have on the outcome of clinical remission. 
The final model will also include interaction terms, if 
necessary, and will be optimised based on fit diagnostics 
and residual analysis. The same approach will be used for 
the secondary outcomes of clinical remission. We will use 
a mixed- effects linear model to study the effects of the 
6 Aardoom MA, et al. BMJ Open 2020;10:e035538. doi:10.1136/bmjopen-2019-035538
Open access 
predictors on the disease activity index over time, taking 
into account the non- independence between the obser-
vations due to the repeated measurements from each 
patient. For the additional long- term secondary outcomes 
that have a time- to- event nature, we will use Kaplan- Meier 
curves to summarise the effects of the categorical factors 
on the outcome. This will be used to build a Cox regres-
sion model with the important factors and covariates that 
have a significant effect on the time and frequency of the 
events as defined in the outcomes section.
Similar methods will be used for the analysis of the 
exploratory outcomes. For these outcomes, propensity 
scores and multivariate methods are required, in partic-
ular for the immunological data, including principal 
component, factor and cluster analysis. Incidences of 
serious adverse events (SAE) and the SAE rate per 100 
patient- years will be calculated. Missing data analysis will 
be performed based on the missing at random or missing 
completely at random mechanisms. Emerging patterns 
will be thoroughly examined.
study status
The first study participant was recruited in 2017. The 
number of included patients up until February 2020 is 
400. Enrolment is expected to be completed by the end 
of 2021.
Patient and public involvement
Patients and/or the public were not involved in the initial 
development, or conduct, or reporting or dissemination 
plans of this research. However, the French patient charity 
AFA Crohn, RCH, France, was involved in the final study 
design and critically reviewed and commented on main 
aspects of the trial.
dIsCussIon
The PIBD- SETQuality inception cohort is a unique study, 
being the first cohort in its size including patients with 
PIBD from European and Asian countries. The homoge-
neous collection of data from several different countries 
in one cohort enables comparison of disease phenotype 
and treatment paradigms between countries and conti-
nents. The hypothesised role of environmental factors in 
the pathogenesis of PIBD might thus be assessed within 
this cohort. In addition, being a cohort with real- world 
data, this study will complement data derived from clin-
ical trials and provide insight in drug use in everyday 
practice and the related international differences.
The main outcome of this study will be the prediction 
of a complicated disease course and response or non- 
response to therapy. One of the important strengths of 
this study is the collection of biomaterial in therapy- naïve 
patients. Studies assessing immunological biomarkers in 
patients with PIBD are scarce and even lacking in therapy- 
naïve patients. The prospective set- up of this study will 
reveal whether immunological biomarkers in PIBD 
change overtime and in response to therapy. In addition, 
these biomarkers can be correlated to the clinical data. 
Besides finding predictive factors of a complicated 
disease course and response to therapy within this real- 
world cohort, we will also use this cohort to examine and 
possibly validate previously reported findings from other 
studies such as the GROWTH CD study.37 38
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